Loading clinical trials...
Loading clinical trials...
A Multicenter, Randomized, 2-Arm, Phase 3 Study to Assess the Efficacy and Safety of a Single Epidural Administration of Resiniferatoxin Versus Standard of Care (SoC) for the Treatment of Intractable Pain Associated With Cancer
Conditions
Interventions
Resiniferatoxin
Standard of Care
Start Date
December 1, 2020
Primary Completion Date
March 1, 2023
Completion Date
March 1, 2023
Last Updated
November 9, 2021
NCT05398003
NCT05761392
NCT04727216
NCT05775510
NCT06897917
NCT06537375
Lead Sponsor
Sorrento Therapeutics, Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions